Home

The Korea Herald

Latest news

Most Popular

  1. 1

    [Exclusive] Korean military set to ban iPhones over 'security' concerns

    [Exclusive] Korean military set to ban iPhones over 'security' concerns
  2. 2

    Korean, Romanian leaders discuss defense tech, nuclear energy

    Korean, Romanian leaders discuss defense tech, nuclear energy
  3. 3

    [Graphic News] 77% of young Koreans still financially dependent

    [Graphic News] 77% of young Koreans still financially dependent
  4. 4

    S. Korea calls on Japan to confront history amid Yasukuni Shrine visit

    S. Korea calls on Japan to confront history amid Yasukuni Shrine visit
  5. 5

    Yoon’s jailed mother-in-law excluded from latest parole list

    Yoon’s jailed mother-in-law excluded from latest parole list
  1. 6

    Hybe and Min Hee-jin, CEO of Hybe sublabel Ador, lock horns

    Hybe and Min Hee-jin, CEO of Hybe sublabel Ador, lock horns
  2. 7

    [Pressure points] Leggings in public: Fashion statement or social faux pas?

    [Pressure points] Leggings in public: Fashion statement or social faux pas?
  3. 8

    Yoo Jae-suk, Yoo Yeon-seok team up in 'Whenever Possible'

    Yoo Jae-suk, Yoo Yeon-seok team up in 'Whenever Possible'
  4. 9

    Korea’s homegrown nanosatellite successfully launches into space

    Korea’s homegrown nanosatellite successfully launches into space
  5. 10

    Aging population to drive down Korea's housing prices from 2040: experts

    Aging population to drive down Korea's housing prices from 2040: experts
피터빈트

Financial authorities reverse decision to delist Kyung Nam Pharm

By Korea Herald

Published : Jan. 8, 2019 - 21:55

    • Link copied

South Korea’s Kosdaq Market Committee on Tuesday scrapped Korea Exchange’s plan to delist local pharmaceuticals company Kyung Nam Pharm from the second-tier Kosdaq market, instead giving the company a one-year grace period to improve transparency.

A panel led by the Korea Exchange, the nation’s sole market operator, last week suggested Kyung Nam Pharm be pulled from the Kosdaq market over accounting errors that occurred between financial years 2008 and 2013.

Due to the errors, revenue of 5 billion won ($4.4 million) was misstated, according to KRX.

Milestone KN Fund is the biggest shareholder of Kyung Nam Pharm, holding 12.48 percent of shares.

(Kyung Nam Pharm.) (Kyung Nam Pharm.)

The initial announcement had spurred questions over whether the panel’s decision was fair, drawing comparison to the case of Samsung BioLogics where the same panel agreed to normalize stock transactions of Samsung BioLogics in late December.

The Securities and Futures Commission suspended trading of the bio firm’s shares for a month due to accounting fraud and the company’s chief executive was levied a fine of 16 million won.  

By The Korea Herald staff (khnews@heraldcorp.com)

More from Headlines